Aktiesnakken — Juni 2013
-
Og det er Levemir, Victoza og NovoRapid der sælger flot derovre. Men både Lilly, GSK og Sanofi kommer jo med nye konkurrerence produkter de næste 1-3 år
-
det var så et tog jeg ikke kom med på (igen)
-
det er også sandt -
mon kina sol siger lidt på siemens melding idag?
-
jeg vil helst have yankee tech eller kina/korea tech
-
dont like europe
-
de lukker solcelle divisionen
-
-
vi skal have drevet noget kapacitet ud af markedet
-
Ikke meget styrke i genmab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind